Search clinical trials for: ASP1517

Total 71 results

Astellas Pharma Inc
FibroGen

Completed

A Study of Intermittent Oral Dosing of ASP1517 in ESA-untreated Chronic Kidney Disease Patients With Anemia

Chronic Kidney Disease

Japan
Astellas Pharma Inc
FibroGen

Completed

A Study of Intermittent Oral Dosing of ASP1517 in Erythropoieses Stimulating Agent (ESA)-Naive Hemodialysis Chronic Kidney Disease Patients With Anemia

ESA-naive Hemodialysis Chronic Kidney Disease Patients With Anemia

Japan
Astellas Pharma Inc
FibroGen

Completed

A Study of Intermittent Oral Dosing of ASP1517 in Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia

Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia

Japan
Astellas Pharma Inc

Completed

ASP1517 Phase 2 Clinical Trial - Double-Blind Study of ASP1517 for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis-

Anemia in Chronic Kidney Disease Patients Not on Dialysis

Japan
Astellas Pharma Global Development, Inc.
FibroGen

Completed

A Study to Assess the Relative Bioavailability of Roxadustat Following a Single Dose of Pediatric Azo Dye-free Tablet Formulation and Pediatric Azo Dye-free Mini-tablet Formulation Compared to a Single Dose of Azo Dye-containing Tablet Formulation in Healthy Adult Subjects

Healthy Adult Subjects

Germany
Astellas Pharma Inc

Completed

ASP1517 Pharmacokinetics Study in Anemia Patients on Hemodialysis

Anemia | Hemodialysis | Renal Impairment

Japan
Astellas Pharma Europe B.V.
FibroGen

Completed

A Phase 1 Study of Roxadustat in Subjects With Different Degrees of Renal Function

Impaired Renal Function | Normal Renal Function

Germany, United Kingdom
Astellas Pharma Inc
FibroGen

Completed

A Food Effect Study to Evaluate the Pharmacokinetics of ASP1517

Healthy Subjects

Japan
Astellas Pharma Inc
FibroGen

Completed

Pharmacokinetic Study of ASP1517 With Kremezin®

Healthy Volunteers

Japan
Astellas Pharma Inc
FibroGen

Completed

A Long Term Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia Converted From Erythropoieses Stimulating Agent (ESA) Treatment

Hemodialysis Patients With Renal Anemia

Japan
Astellas Pharma Inc

Active, not recruiting

Post-marketing Surveillance of EVRENZO® Tablets (Roxadustat) in Patients With Renal Anemia

Renal Anemia

Japan
Astellas Pharma Inc

Completed

Safety, Tolerability and Pharmacokinetic Study of ASP1517 in Healthy Non-elderly Male Volunteers

Healthy Volunteers

Japan
Astellas Pharma Global Development, Inc.

Completed

A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome | Acute Myeloid Leukemia (AML)

United States, Japan
Astellas Pharma Inc
FibroGen

Completed

A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP1517 and Lanthanum Carbonate Hydrate

Healthy Subjects

Japan
Maruho Co., Ltd.

Completed

Phase III Study of ASP2151 in Herpes Simplex Patients

Herpes Simplex

Japan
Astellas Pharma Inc
FibroGen

Completed

A Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia

Hemodialysis Chronic Kidney Disease Patients With Anemia

Japan
Astellas Pharma Global Development, Inc.

Completed

Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP1617 in Healthy Adult Non-Asian and Japanese Subjects Including Assessment of a Food Effect

Healthy Volunteers

United States
Astellas Pharma Inc

Completed

A Study to Assess the Systemic Disposition of ASP1585 After Administration of 14C-labeled Drug

Healthy | Pharmacokinetics of ASP1585

United States
Astellas Pharma Europe B.V.
FibroGen

Completed

A Study to Evaluate the Effects of Multiple Doses of FG-4592 on the Exposure, Safety and Tolerability and Effect of Warfarin in Healthy Subjects

Healthy Subjects | Pharmacokinetics of FG-4592

Germany
Astellas Pharma Europe B.V.
FibroGen

Completed

A Study to Investigate the Exposure and Safety and Tolerability of a Single Dose of FG-4592 in Subjects With Moderately Diminished Liver Function Compared to Those With Normal Liver Function

Hepatic Insufficiency | Healthy Subjects | PK of FG-4592

Bulgaria
Astellas Pharma Inc

Terminated

A Study to Evaluate the Effect of ASP8597 in Adult Kidney Transplant Patients

Kidney Transplantation

United States
Astellas Pharma Europe Ltd.

Completed

Study to Evaluate the Safety and Pharmacokinetics of Single Doses of ASP2151 in Healthy Male Subjects and the Effects of Food

Herpes Zoster | Herpes Genitalis

France
Astellas Pharma Inc
FibroGen

Completed

A Study of Intermittent Oral Dosing of ASP1517 in Non-Dialysis Chronic Kidney Disease Patients With Anemia

Chronic Kidney Disease

Japan
Astellas Pharma Inc

Completed

Dose Range-finding Study of ASP1585 in Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia

Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia

Japan
Astellas Pharma Inc

Completed

Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis

Renal Insufficiency | Chronic Kidney Disease | Hyperphosphatemia

Japan
Astellas Pharma Inc

Completed

A Study to Investigate the Effect of ASP1517 After Intermittent Oral Dosing in Dialysis Chronic Kidney Disease Patients With Anemia Compared With Darbepoetin as a Reference Drug

Renal Anemia Associated With Chronic Renal Failure (CRF)

Japan
Astellas Pharma Inc

Completed

A Study of ASP1585 to Evaluate the Bioequivalence Between ASP1585 Granules and ASP1585 Capsules

Healthy | Urine Phosphorus Excretion

Japan
Astellas Pharma Inc

Completed

A Phase 3 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis

Renal Insufficiency | Chronic Kidney Disease | Hyperphosphatemia

Japan
Astellas Pharma Inc

Completed

Study to Evaluate the Safety and Pharmacokinetics of ASP2151 in Healthy Non-elderly and Elderly Subjects

Healthy Subjects

Japan
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Effects of Single Ascending Doses of ASP1707 in Healthy Young Japanese Male Subjects

Healthy Subjects

United Kingdom
FibroGen
AstraZeneca; Astellas Pharma Inc

Terminated

Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden

Anemia | Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts)

United States, Australia, Belgium, Germany, Israel, Italy, Korea, Republic of, Russian Federation, Spain, United Kingdom, France, Turkey, Canada, Denmark, India, Poland
Astellas Pharma Global Development, Inc.

Recruiting

A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease

Chronic Kidney Disease | Renal Anemia

Romania, Spain, Belgium, Germany, Norway, Slovakia, Denmark, Czechia, Lithuania, United Kingdom, Lebanon, Greece, Ireland, Croatia, Bulgaria
Astellas Pharma Global Development, Inc.

Recruiting

A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas

B-cell Lymphoma

Australia
Astellas Pharma Inc

Completed

Post-marketing Surveillance of Kiklin Capsules in Hemodialysis Patients

Chronic Renal Failure Patients With Hyperphosphataemia Receiving Hemodialysis

Japan
Astellas Pharma Europe B.V.
FibroGen

Completed

A Study to Evaluate the Dose-proportionality and Effects of FG-4592 in Healthy Young and Elderly Male and Female Subjects

Healthy Subjects | PK for FG-4592

Germany
Astellas Pharma Inc

Completed

Long-term Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis

Renal Insufficiency | Chronic Kidney Disease | Hyperphosphatemia | Renal Dialysis

Japan
Astellas Pharma Inc

Completed

A Phase 3 Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Peritoneal Dialysis

Renal Insufficiency | Chronic Kidney Disease | Renal Dialysis

Japan
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Effect of ASP1707 on the Bodies of Healthy Male Subjects After a Single Dose of Radioactive ASP1707

Pharmacokinetics of ASP1707

United Kingdom
Astellas Pharma Inc

Completed

Post-marketing Surveillance of Bixalomer in Patients With Pre-dialysis Chronic Kidney Disease

Chronic Kidney Disease

Japan
Maruho Co., Ltd.

Completed

Open-label Study of ASP2151 in Herpes Simplex Patients

Herpes Simplex

Japan
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Safety, Tolerability and Effects of Single and Multiple Ascending Doses of ASP1707 in Healthy Male and Pre-menopausal Female Subjects, Including a Comparison of the Effects Under Fasted and Fed Conditions in Healthy Young Male Subjects

Pharmacokinetics of ASP1707 | Pharmacodynamics of ASP1707

France
Astellas Pharma Inc

Completed

Post-Marketing Surveillance on Long-Term Drug Use of Kiklin (Bixalomer)® Capsules in Patients With Hyperphosphatemia Receiving Peritoneal Dialysis

Chronic Renal Failure

Japan
FibroGen
AstraZeneca; Astellas Pharma Europe B.V.

Completed

Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants (Himalayas)

Anemia in Incident Dialysis Patients

Russian Federation, Bulgaria, Thailand, United States, Argentina, Chile, Colombia, Korea, Republic of, Latvia, Malaysia, Mexico, Poland, Romania, Taiwan, Ukraine
Astellas Pharma Europe B.V.
FibroGen

Completed

Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis (ALPS)

Anemia in Chronic Kidney Disease in Non-dialysis Patients

Spain, Belarus, Bulgaria, Hungary, Poland, Romania, Russian Federation, Serbia, Ukraine, United Kingdom, Belgium, Georgia, Italy, Colombia, Dominican Republic, Estonia, Greece, Guatemala, Panama, Peru, South Africa, Turkey
FibroGen
AstraZeneca; Astellas Pharma Europe B.V.

Completed

A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving Dialysis

CKD Anemia

United States, Australia, Thailand, Korea, Republic of, Malaysia, Mexico, Taiwan, New Zealand, Argentina, Chile, Colombia, Hong Kong, Peru, Philippines, Puerto Rico, Singapore
Astellas Pharma Europe B.V.
FibroGen

Completed

Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa (Dolomites)

Anemia in Chronic Kidney Disease in Non-dialysis Patients

Austria, Belarus, Bulgaria, Croatia, Czechia, Finland, France, Georgia, Germany, Hungary, Ireland, Israel, Latvia, Montenegro, Netherlands, North Macedonia, Poland, Portugal, Romania, Russian Federation, Serbia, Slovakia, Slovenia, Spain and more
Astellas Pharma Global Development, Inc.

Completed

Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen

Advanced Cancer | Advanced Malignancies

United States
Astellas Pharma Inc

Completed

A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes

Herpes Genitalis

United States
Maruho Co., Ltd.

Completed

Phase III Study of ASP2151 in Herpes Zoster Patients

Herpes Zoster

Japan
Astellas Pharma Inc

Completed

Dose-finding Study of ASP2151 in Subjects With Herpes Zoster

Herpes Zoster

Japan

3

Subscribe